IMCB NCC MPI SOG   
                       
    Main Page   Staff Directory   Publications          
                       
   
a filler
  Boon Tin CHUA  
  Lab Location: #6-19

email:
btchua@imcb.a-star.edu.sg
tel:65869875

 
a a a
a a a
  Key Publications  
 

Ho HK, Ng YR, Nemeth G, Szántai-Kis C, Breza N, Szokol B, Baska F, Őrfi L, Ullrich A, Kéri G and Chua BT (2013). Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design supported by in vitro and cell-based testing.
Current Medicinal Chemistry (E-pub Jan 28 2013)

Poh WJ, Wong W, Ong HM, Aung MO, Lim SG, Chua BT and Ho HK (2012).
Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma.
Molecular Cancer.11:14

Chua BT, Lim SJ, Tham SC, Poh WJ and Ullrich A (2010). Somatic mutation of ACK1 at ubiquitin-association domain enhances mitogenic signaling through EGFR regulation in kidney carcinoma.
Molecular Oncology, 4, 323-334

Sukumaran SK, Fu NY, Chua BT, Wan KF, Lee SS and Yu VC (2010).
A soluble form of the pilus protein FimA targets the VDAC-hexokinase complex at mitochondria to suppress host cell apoptosis.
Molecular Cell, 37, 768-783

Chua BT, Gallego-Ortega D, De Molina AR, Ullrich A, Lacal JC and Downward J (2009).  Regulation of Akt(ser473) phosphorylation by Choline Kinase in breast carcinoma cells.
Molecular Cancer, 8:131

Volbracht C, Chua BT, Ng CP, Bahr BA, Hong W, Li P (2005). The critical role of calpain versus caspase activation in excitotoxic injury induced by nitric oxide. J Neurochem, 93(5), 1280-92. Erratum in: Journal of Neurochemistry. 94(5), 1471.

Chua BT, Volbracht C, Tan KO, Li R, Yu VC, Li P (2003). Mitochondrial translocation of cofilin is an early step in apoptosis induction.
Nature Cell Biology, 5(12), 1083-9.

Chua BT, Guo K, Li P. (2000). Direct cleavage by the calcium-activated protease calpain can lead to inactivation of caspases. Journal of Biological Chemistry. 275(7), 5131-5. .

 
a a a
 
  Boon Tin CHUA


Boon Tin graduated with B.Sc (Hons in Biochemistry) from Imperial College of Science, Technology and Medicine in 1998. She received her PhD training at the Institute of Molecular and Cell Biology, Singapore with Dr Peng Li.

Upon graduation in 2004, she was awarded Post-doctoral training Fellowship by Cancer Research UK, expanding her apoptosis background with Dr Julian Downward's Signal Transduction Laboratory in Lincoln's Inn Fields, London. During her post-doctoral training, she set up a human kinome siRNA library screen to identify Akt regulators.

She joined Singapore Oncogenome Project (SOG) in March 2007 as a research fellow characterizing somatic mutations identified on tyrosine kinases (TKs) in cancer cells. In 2009, she was appointed the project leader of SOG with Prof Axel Ullrich as the scientific advisor and mentor. On the same year, she was also awarded the inaugural A*STAR-NKTH joint grant for the development of small molecule inhibitors against TKs. Her current research focuses on exploring novel tyrosine kinases as anti-cancer therapeutics with the aim to develop tyrosine kinase inhibitor for cancer treatment.

     
  IMCB NCC MPI Singapore Oncogenome Program
 


IMCB NCC MPI Singapore Oncogenome Program is a collaborative unit funded by Max Planck - Department of Biochemistry, National Cancer Centre Singapore and Institute of Molecular and Cell Biology. The unit houses both basic and clinical research, providing a synergistic research environment for translational work in the field of oncology. The unit serves to link both clinicians and basic scientists with common research interests to explore, discuss, and develop ideas. 

As a start, 3 clinicians from the National Cancer Center Singapore will function as adjunct investigators in the laboratory.



Darren Wan-Teck Lim

Dr Darren Wan-Teck Lim is a medical oncologist.  He graduated with MBBS from the National University of Singapore in 1993.  He is Director of the SingHealth Investigational Medicine Unit.  He was a visiting research fellow in pharmacogenomics and thoracic oncology at the Washington University School of Medicine, St Louis.  His research interests are in early phase clinical trials with biomarker correlates, with areas of specific interest in circulating tumor cells.  He is also Co-Group Leader for the laboratory. 

 



Gopal Iyer

Dr Gopal Iyer is head and neck cancer surgeon.  He graduated with MBBS from the National University of Singapore in 1998 with the Lee Kuan Yew Gold Medal and the Gibbs Gold Medal.  He also holds a PhD in Cancer Genomics from Cambridge University.  He completed his postdoctoral fellowships with the Cancer Genomics Program, Cambridge University and at the Genome Institute of Singapore.    His research interests are in squamous cell carcinoma of the head and neck focusing on the biology of head and neck cancer stem cells and investigating novel drug targets and pathways in head and neck cancer.  He is also the recipient of the NMRC Clinician Scientist Award for his research in 2012.

 



Daniel Shao-Weng Tan

Dr Daniel Shao-Weng Tan is a medical oncologist.  He graduated from University College London, with an Intercalated Bachelor of Science degree in Tumour Biology, 1st Class (Honours), and MBBS from St. Bartholomew’s and Royal London Hospital School of Medicine and Dentistry.   He has received the ASCO Cancer Foundation Young Investigator Award and ASCO Cancer Foundation Merit Award.  His research interests are in drug development in phase I trials.  He is directly involved in developing protocols testing new drug targets and combinations in various cancers.  His areas of specific interest are in drug resistance, with particular emphasis on lung cancer and the PI3K pathway.

 

Capabilities

      1. Molecular profiling of cancer to identify novel targets
      2. Functional characterization of oncogenes
      3. Primary cancer cell lines and xenograft model for disease    characterization and drug testing
      4. Small molecule inhibitor development under the SOG program
      5. Investigate and repurpose established drugs